Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1058 posts found.

Cancer Research UK joins forces with Teon to develop new cancer drug

March 2, 2021
Manufacturing and Production Cancer, Cancer Research UK, Teon

Cancer Research UK and Teon Therapeutics have entered a collaboration agreement to progress the early phase clinical development of Teon’s new cancer drug. The partnership …

News

Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal

March 1, 2021
Sales and Marketing Cancer, Kazia, Oasmia

Oasmia Pharmaceutical, an innovation-focused specialty pharmaceutical company, is set to acquire exclusive global development rights for Kazia Therapeutics’ ovarian cancer …

News

Ipsen receives CHMP recommendation for Cabometyx in combination with Opdivo

March 1, 2021
Sales and Marketing Cancer, EMA, ipsen

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Ipsen’s Cabometyx (cabozantinib) in combination with …

News

NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer

February 26, 2021
Medical Communications Cancer, NICE, Novartis

NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …

News

New research article confirms role of masitinib as a potential pancreatic cancer therapy

February 25, 2021
AB Sciences, Cancer, masitinib

A recently published, peer-reviewed research article has concluded that the inhibition of mast cells with AB Science’s masitinib could represent …

News
libtayo

FDA approves Regeneron & Sanofi’s Libtayo for advanced non-small cell lung cancer

February 23, 2021
Manufacturing and Production Cancer, Sanofi

The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …

News

ONK and Anthony Nolan combine forces to work on blood cancer therapies

February 22, 2021
Sales and Marketing Anthony Nolan, Cancer, ONK, blood cancer, cancer treatment

ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) …

News
minaris-mg_7425-web

MaxiVAX and Minaris sign manufacturing deal for cell-based cancer immunotherapy

February 22, 2021
Sales and Marketing Cancer, MaxiVAX, Minaris

MaxiVAX and Minaris Regenerative Medicine have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of …

News
tukysa

Seagen’s breast cancer drug TUKYSA gets UK approval

February 22, 2021
Sales and Marketing Cancer, MHRA, Seagen

The MHRA has granted marketing authorisation in the UK for Seagen’s TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, for …

News

New Cell Guidance technology has potential to help treat cancer

February 19, 2021
Medical Communications Cancer, cancer treatment, cell guidance systems, macrophages, pharma news

Cell Guidance Systems’ new POlyhedrin Delivery System (PODS) technology has been shown to have therapeutic potential in the treatment of …

News
nektar-therapeutics

Nektar and SFJ collaborate to develop experimental head and neck cancer drug

February 18, 2021
Cancer, Nektar Therapeutics

Nektar Therapeutics has announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG), an investigational CD122-preferential …

News
lynparza

AstraZeneca and MSD’s Lynparza crosses superiority boundary for invasive disease-free survival

February 17, 2021
Research and Development AstraZeneca, Cancer, MSD

The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …

News
enhertu

Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu approved in UK

February 16, 2021
Manufacturing and Production AstraZeneca, Cancer, Daiichi Sankyo

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted conditional authorisation in the UK as a monotherapy for the …

News
fdaoutsideweb

FDA approves Sanofi’s Libtayo for advanced basal cell carcinoma

February 10, 2021
Research and Development Cancer, FDA, Sanofi

The FDA has approved Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell …

News
janssen_latest_logo_on_sign

Janssen announces positive Phase III results for prostate cancer drug apalutamide

February 10, 2021
Research and Development Cancer, Janssen

Final results from Janssen’s Phase III TITAN study have shown its cancer drug apalutamide improved overall survival (OS) in patients …

News

Latest content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024